Brainy efforts underway, but still some way to go for neuro drug developers
Main U.S. indexes sharply higher; Nasdaq, Dow up 1.3%
Cons Disc leads S&P sector gainers; Utilities sole loser
Euro STOXX 600 index up 1.3%
Dollar rises; gold edges up; crude, up >1%, bitcoin up 0.4%
U.S. 10-Year Treasury yield edges up to ~4.33%
Welcome to the home for real-time coverage of markets brought to you by Reuters reporters. You can share your thoughts with us at markets.research@thomsonreuters.com
BRAINY EFFORTS UNDERWAY, BUT STILL SOME WAY TO GO FOR NEURO DRUG DEVELOPERS
An unmet need in neurological conditions has stirred up anticipation for trial data for drugs being developed for neurological conditions like depression, Alzheimer's disease, and dementia that affect millions of patients worldwide, Canaccord Genuity analysts said on Friday.
The brokerage said some recent wins with Eisai 4523.T and Biogen's BIIB.O Leqembi and Eli Lilly's LLY.N Kisunla for Alzheimer's, along with Bristol Myers Squibb's BMY.N Cobenfy for schizophrenia, represent significant advances in their fields.
It estimates that about 57 products are in development for major depressive disorder, including 14 for treatment-resistant depression, 11 for bipolar depression, and 5 for postpartum depression that affects new mothers.
Canaccord said it is looking forward to late-stage trial data from Johnson & Johnson's JNJ.N aticaprant and Neumora Therapeutics' NMRA.O navacaprant, both in development for major depressive disorder.
"Overall, we believe biopharma's depression-focused pipeline remains healthy" said Canaccord, but added that there was still a long way to go due to some diseases being poorly understood.
Canaccord added that successes in Alzheimer's with Leqembi and Kisunla have come despite the challenges in understanding such neurodegenerative conditions.
Among newer drugs in development, the brokerage highlighted Roche's ROG.S trontinemab, designed to ferry the drug across the blood brain barrier—protective blood vessels that prevent chemicals in the bloodstream from entering the brain - in hopes of getting more of the treatment into the brain.
Canaccord said Cervomed's CRVO.O neflamapimod could be a "major advance for patients."
Cervomed is developing the drug to treat dementia with Lewy bodies, the second most common type of dementia after Alzheimer's and an indication that sees fewer investments, said Canaccord.
(Christy Santhosh)
*****
FOR FRIDAY'S EARLIER LIVE MARKETS POSTS:
JOBS REPORT DRILL-DOWN: IS DIRE DATA A BLIP OR TREND? - CLICK HERE
U.S. STOCKS RISE AFTER PAYROLLS AS AMAZON LEADS - CLICK HERE
U.S. STOCK FUTURES ADD SLIGHTLY TO GAINS, YIELDS FALL, AFTER JOBS DISAPPOINT - CLICK HERE
COULD OCTOBER PAYROLLS BE NEGATIVE? - CLICK HERE
EUROPEAN EARNINGS: BETTER BUT STILL MIXED - MORGAN STANLEY - CLICK HERE
UK GILTS: TRUSSED UP? - CLICK HERE
EUROPEAN SHARES BOUNCE, STILL SET FOR WEEKLY FALL - CLICK HERE
EUROPE BEFORE THE BELL: FUTURES STEADY BEFORE JOBS DATA - CLICK HERE
A NOVEMBER TO REMEMBER... -CLICK HERE
Early trade Nov 1 https://tmsnrt.rs/4f6WHRV
Nonfarm payrolls https://reut.rs/3AaNOYA
Inflation gauges https://reut.rs/40sVSP5
Labor market participation https://reut.rs/4easqAj
Unemployment by duration https://reut.rs/3YKrmPl
Unemployment by race and ethnicity https://reut.rs/48u6jDK
Related Assets
Latest News
Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.
All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.
Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.
